INDV N Stock Overview Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. More details
Rewards Risk Analysis No risks detected for INDV N from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Indivior Historical stock prices Current Share Price UK£314.49 52 Week High UK£0 52 Week Low UK£0 Beta -0.17 1 Month Change -51.30% 3 Month Change -51.30% 1 Year Change -51.30% 3 Year Change n/a 5 Year Change n/a Change since IPO -51.30%
Recent News & Updates Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial Officer
Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment Nov 20
Jerome Lande to Step Down from the Board of Indivior plc Nov 15
Oaktree Capital Sends a Letter to Indivior PLC Nov 07 Indivior PLC Revises Financial Guidance for the Fiscal Year 2024
Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review Oct 07 See more updates Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial Officer
Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment Nov 20
Jerome Lande to Step Down from the Board of Indivior plc Nov 15
Oaktree Capital Sends a Letter to Indivior PLC Nov 07 Indivior PLC Revises Financial Guidance for the Fiscal Year 2024
Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review Oct 07
Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board Oct 04
Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder Sep 04
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Aug 27
Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers Aug 03 Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million. Jul 27
Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024 Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)
Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression Jun 19
Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder Jun 13
Indivior plc Reaffirms Revenue Guidance for the Year 2024 May 25
Indivior PLC Announces Board Committee Changes May 11
Indivior plc Reconfirms Earnings Guidance for 2024 Apr 27
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024 Mar 22 Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024
Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone Mar 12
Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024 Jan 20
Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million. Nov 18
Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023 Nov 11
Indivior PLC Announces Executive Changes Nov 09
Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023 Oct 24
Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023 Oct 06
Two Seas Capital Provides Information to Shareholders of Indivior PLC Oct 05
Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023 Oct 01
Indivior PLC Revises Earnings Guidance for the Year 2023 Jul 29
Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023 Jun 29
Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023 Jun 28
Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl May 23
Indivior PLC Announces Board and Committee Changes Feb 17
Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023 Jan 12
Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022 Dec 07
Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million. Nov 16
Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million. Nov 15
Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims Oct 25
Investor sentiment deteriorated over the past week Oct 10
Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022 Oct 05
Indivior PLC, Annual General Meeting, Sep 30, 2022 Sep 07
Indivior PLC, Annual General Meeting, Sep 30, 2022 Sep 06
Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S Aug 26
Indivior PLC Provides Revenue Guidance for the Full Year Jul 30
Indivior plc Announces Executive Changes Jul 29
Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021) Jul 28
Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022 Jul 08
Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film Jun 25
Indivior Names Nina DeLorenzo Chief Global Impact Officer Jun 17
Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder Jun 02
First quarter 2022 earnings released: EPS: US$0.06 (vs US$0.11 in 1Q 2021) Apr 29
Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022 Apr 28
High number of new directors Apr 27
Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC Apr 26
Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users Apr 09
Indivior PLC, Annual General Meeting, May 05, 2022 Apr 02
Full year 2021 earnings released: EPS: US$0.28 (vs US$0.20 loss in FY 2020) Apr 01
Indivior PLC, Annual General Meeting, May 05, 2022 Mar 31
Chief Human Resources Officer recently sold Mex$12m worth of stock Mar 18
Chief Commercial & Strategy Officer recently sold Mex$22m worth of stock Feb 20
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
Indivior PLC Provides Revenue Guidance for the Year 2022 Feb 16
Indivior PLC to Report Fiscal Year 2021 Results on Feb 16, 2022 Feb 02
Indivior PLC Announces Results from Buprenorphine-Fentanyl Interaction Study in PLOS ONE Jan 29
Third quarter 2021 earnings released: EPS US$0.04 (vs US$0.014 in 3Q 2020) Oct 30
Independent Non-Executive Chairman recently bought Mex$1.4m worth of stock Aug 07
Second quarter 2021 earnings released: EPS US$0.08 (vs US$0.025 in 2Q 2020) Jul 31
Indivior PLC Raises Revenue Guidance for the Fiscal Year 2021 Jun 30
Indivior PLC Presents New Data at the College on Problems of Drug Dependence 2021 Annual Conference Jun 25
Senior Independent Director has left the company May 12
First quarter 2021 earnings released: EPS US$11.00 (vs US$0.22 loss in 1Q 2020) May 01
Indivior PLC Reiterates Guidance for Year 2021 Apr 30
Full year 2020 earnings released: US$0.20 loss per share (vs US$0.18 profit in FY 2019) Apr 03
Full year 2020 earnings released: US$0.20 loss per share (vs US$0.18 profit in FY 2019) Feb 20
Revenue misses expectations Feb 20 Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)
Indivior PLC to Report Fiscal Year 2020 Results on Feb 18, 2021 Jan 15
Indivior PLC Announces Resignation of DanielTassé as Non-Executive Director Jan 12
Reckitt Benckiser Group Submits Claim against Indivior PLC Nov 28 Shareholder Returns INDV N MX Pharmaceuticals MX Market 7D -51.3% -3.4% -2.9% 1Y -51.3% -27.4% -14.0%
See full shareholder returns
Return vs Market: INDV N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility Is INDV N's price volatile compared to industry and market? INDV N volatility INDV N Average Weekly Movement 0% Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.0% 10% least volatile stocks in MX Market 2.6%
Stable Share Price: INDV N's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine INDV N's volatility change over the past year.
About the Company Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex.
Show more Indivior PLC Fundamentals Summary How do Indivior's earnings and revenue compare to its market cap? INDV N fundamental statistics Market cap Mex$42.64b Earnings (TTM ) Mex$3.03b Revenue (TTM ) Mex$16.73b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) INDV N income statement (TTM ) Revenue US$838.00m Cost of Revenue US$140.00m Gross Profit US$698.00m Other Expenses US$546.00m Earnings US$152.00m
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 27, 2022
Earnings per share (EPS) 1.10 Gross Margin 83.29% Net Profit Margin 18.14% Debt/Equity Ratio 104.3%
How did INDV N perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2022/10/11 00:47 End of Day Share Price 2022/10/10 00:00 Earnings 2022/06/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Indivior PLC is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Graham Glyn Parry BofA Global Research Brian White Cantor Fitzgerald Europe Chase Knickerbocker Craig-Hallum Capital Group LLC
Show 14 more analysts 